CN118284414A - 血清素再摄取抑制剂戒断综合征的治疗 - Google Patents

血清素再摄取抑制剂戒断综合征的治疗 Download PDF

Info

Publication number
CN118284414A
CN118284414A CN202280058839.3A CN202280058839A CN118284414A CN 118284414 A CN118284414 A CN 118284414A CN 202280058839 A CN202280058839 A CN 202280058839A CN 118284414 A CN118284414 A CN 118284414A
Authority
CN
China
Prior art keywords
escitalopram
gentisate
symptoms
subject
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280058839.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·哈斯莱顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN118284414A publication Critical patent/CN118284414A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
CN202280058839.3A 2021-07-06 2022-07-06 血清素再摄取抑制剂戒断综合征的治疗 Pending CN118284414A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163218535P 2021-07-06 2021-07-06
US63/218,535 2021-07-06
PCT/IB2022/056229 WO2023281406A1 (en) 2021-07-06 2022-07-06 Treatment of serotonin reuptake inhibitor withdrawal syndrome

Publications (1)

Publication Number Publication Date
CN118284414A true CN118284414A (zh) 2024-07-02

Family

ID=82942712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280058839.3A Pending CN118284414A (zh) 2021-07-06 2022-07-06 血清素再摄取抑制剂戒断综合征的治疗

Country Status (8)

Country Link
US (1) US20240277654A1 (https=)
EP (1) EP4366726A1 (https=)
JP (1) JP2024529009A (https=)
KR (1) KR20240117521A (https=)
CN (1) CN118284414A (https=)
AU (1) AU2022308198A1 (https=)
CA (1) CA3227324A1 (https=)
WO (1) WO2023281406A1 (https=)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
US8206735B2 (en) 2006-07-11 2012-06-26 Foresee Pharmaceuticals, Llc Pharmaceutical compositions for sustained release delivery of peptides
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
WO2009148580A2 (en) 2008-06-03 2009-12-10 Qlt Usa, Inc. Controlled release copolymer formulation with improved release kinetics
RU2504360C2 (ru) 2008-08-12 2014-01-20 Новартис Аг Фармацевтические композиции
PT2355853T (pt) 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
CA2792484C (en) 2009-03-12 2017-10-31 Delpor, Inc. Implantable device for long-term delivery of drugs
AU2016228315B2 (en) * 2009-09-17 2018-01-04 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
HUE060304T2 (hu) 2010-01-04 2023-02-28 Mapi Pharma Ltd Glatiramer acetátot tartalmazó depó rendszer
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
US9023897B2 (en) 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
HRP20192276T1 (hr) 2011-06-10 2020-05-15 Ramscor, Inc. Formulacije s produljenim oslobađanjem za dostavu proteina u oko i postupci njihove pripreme
US20130144250A1 (en) 2011-10-24 2013-06-06 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
BR112014017969A8 (pt) 2012-01-23 2017-07-11 Allergan Inc Microesferas ou micropartículas bioerodíveis ou bio-degradáveis liberadas por tempo suspensas em uma formulação de droga injetável de formação de depósito
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
US9943484B2 (en) 2013-06-20 2018-04-17 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN111194312A (zh) * 2017-10-09 2020-05-22 提瓦制药工业公司 依地普仑的新盐和固态形式

Also Published As

Publication number Publication date
US20240277654A1 (en) 2024-08-22
WO2023281406A1 (en) 2023-01-12
JP2024529009A (ja) 2024-08-01
EP4366726A1 (en) 2024-05-15
AU2022308198A1 (en) 2024-02-01
CA3227324A1 (en) 2023-01-12
KR20240117521A (ko) 2024-08-01

Similar Documents

Publication Publication Date Title
AU2014261329B2 (en) Fenfluramine for use in the treatment of dravet syndrome
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
EP1001760B1 (en) Composition for controlling mood disorders in healthy individuals
EP3645120B1 (en) Nk-1 antagonist compositions and methods for use in treating depression
US20260027057A1 (en) Therapeutic formulations and uses thereof
WO2005065308A2 (en) Compositions and methods to treat recurrent medical conditions
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
EP4729123A2 (en) Compositions comprising pramipexole and a 5ht3 antagonist for use in treating depression
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
CN118284414A (zh) 血清素再摄取抑制剂戒断综合征的治疗
WO2024102802A1 (en) Zelatriazin for the treatment of depression
TWI864376B (zh) 焦慮症處置用組成物及處置方法
KR101978459B1 (ko) 조루증 치료용 약학 조성물 및 조루증 치료 방법
US20240100012A1 (en) Pharmaceutical dosage form
US8680145B1 (en) Compositions and methods for treatment of fear of medical procedures
CN110075302A (zh) 一种治疗抑郁和失眠的组合物及其用途
CN101304746A (zh) 氟班色林在治疗绝经前性欲障碍中的用途

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination